
1. Technology overview
Strand AI Bio Corp. is a Delaware corporation doing business as Strand AI, founded in 2026 according to its About page and part of Y Combinator's Winter 2026 batch in San Francisco. It builds foundation models that generate biological data missing from patient records, so that biopharma teams can select trial patients with fuller information.
Its first model, Lattice, predicts spatially resolved protein-marker maps from routine H&E slides as virtual multiplex immunofluorescence channels. Customers send digitized slides, the company runs Lattice plus cell segmentation and tumor microenvironment analysis, and returns structured data with a written readout; deployment inside a customer environment is also offered.
2. Highlighted features & specifications
- Virtual multiplex channels: Lattice predicts protein-marker maps from H&E slides at the resolution of the underlying image.
- Pan-cancer coverage: trained across a broad span of tumor and tissue types and more than a hundred protein markers.
- Spatial analysis: cell segmentation, phenotyping and tumor microenvironment characterization on top of predictions.
- Written readout: structured spatial data and an analysis aimed at the customer's biomarker question.
- In-environment deployment: runs inside the customer's institution for cohorts that cannot leave it.
3. Potential application
Biopharma teams could stratify patients in archived trial cohorts by tumor microenvironment. Pathology and translational research groups could triage samples before paying for real multiplex assays. Diagnostics companies could scope custom marker panels.
4. Benefits
Predictions are computational, so archival tissue blocks are not consumed. Whole cohorts can be profiled rather than a few selected sections. Customers do not need to install, validate or staff the pipeline. Custom model partnerships can be scoped around a specific target or marker panel.
5. Market trends & opportunities
Pharma sponsors increasingly rely on multimodal patient data to choose trial populations, yet most patients lack assays such as spatial proteomics. Computational imputation from routine slides is one route to extend retrospective cohorts without new wet-lab work, relevant to biopharma and research hospitals in Asia.
6. Other information
Strand AI Bio Corp., a Delaware corporation per its privacy policy; Y Combinator Winter 2026 batch, San Francisco per YC listing. The About page states it was founded in 2026.
One platform connecting startups, corporations, research institutions, regions and investors











Playbook & Handbook · February 6, 2026
Winning Accelerator Playbook 2026 by BambuUP
RETAIL E-COMMERCE: AI AND REAL-TIME DATA ARE TRANSFORMING HOW RETAIL BUSINESSES OPERATE








































